Literature DB >> 19608177

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.

Nanette L Rollene1, Mark H Amols, Susan B A Hudson, Charles C Coddington.   

Abstract

OBJECTIVE: To describe an outpatient treatment protocol for ovarian hyperstimulation syndrome (OHSS) that results in rapid normalization of symptoms with minimal side effects.
DESIGN: Case series.
SETTING: Midwestern academic reproductive endocrinology division. PATIENT(S): Four consecutive patients, diagnosed with OHSS, who presented after oocyte retrieval but before embryo transfer. INTERVENTION(S): All embryos were frozen and each patient was treated with the same dopamine agonist and GnRH antagonist protocol. MAIN OUTCOME MEASURE(S): Daily weights, days to resolution of clinical symptoms, side effects of the treatment protocol, and whether or not acute care or hospitalization was necessary. RESULT(S): The most rapid weight loss was within the first 5 days of treatment. The average time to resolution of clinical symptoms was 5.75 days. No side effects were reported and no patients required acute care or hospitalization. CONCLUSION(S): Dopamine agonists and GnRH antagonists, when given together at the time of diagnosis of OHSS, appear to work rapidly and effectively to diminish the clinical symptoms of the disease. The potential benefit of finding an outpatient treatment for OHSS with rapid onset and minimal side effects warrants further investigation into this protocol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608177     DOI: 10.1016/j.fertnstert.2009.05.062

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  13 in total

1.  Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.

Authors:  Aalie Torabizadeh; Fatemeh Vahidroodsari; Zakieh Ghorbanpour
Journal:  Iran J Reprod Med       Date:  2013-10

Review 2.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

3.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

4.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

5.  Treatment results of high dose cabergoline as an adjuvant therapy in six patients with established severe ovarian hyper stimulation syndrome.

Authors:  Nasrin Saharkhiz; Azadeh Akbari Sene; Saghar Salehpour; Maryam Tamimi; Masoumeh Vasheghani Farahani; Kourosh Sheibani
Journal:  Iran J Reprod Med       Date:  2014-10

6.  Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study.

Authors:  Ya-Qin Wang; Nan Yu; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jing Yang
Journal:  Exp Ther Med       Date:  2014-10-06       Impact factor: 2.447

7.  Outcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndrome.

Authors:  Shohreh Movahedi; Leili Safdarian; Marzieh Agahoseini; Ashraf Aleyasin; Sepideh Khodaverdi; Sara Asadollah; Ali Kord Valeshabad; Parvin Fallahi; Zahra Rezaeeian
Journal:  Med J Islam Repub Iran       Date:  2016-05-17

Review 8.  The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.

Authors:  Neil Chappell; William E Gibbons
Journal:  Clin Exp Reprod Med       Date:  2017-06-30

9.  Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome.

Authors:  Travis J O'Brien; Arthur F Harralson; Tuyen Tran; Ian Gindoff; Funda E Orkunoglu-Suer; David Frankfurter; Paul Gindoff
Journal:  Reprod Biol Endocrinol       Date:  2014-05-09       Impact factor: 5.211

10.  GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.

Authors:  Usama M Fouda; Ahmed M Sayed; Hesham S Elshaer; Bahaa Eldin M Hammad; Mona M Shaban; Khaled A Elsetohy; Mohamed A Youssef
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.